UPDATE: Intersect ENT (XENT) Posts Q2 Loss of $2.36/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT Reports Second Quarter 2014 Results
September 3, 2014 4:01 PM EDTMENLO PARK, Calif., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter of 2014.
Recent Accomplishments
Achieved Q2 revenue of $8.6 million, an increase of 118% over the second quarter of 2013  Realized gross margin of 73%, an increase of 66% from 44% in the second quarter of the prior year  Completed an initial public offering, raising $63.3M in gross proceeds  Completed the RESOLVE clinical study... More